Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADRC for Hip Osteonecrosis
NCT03269409Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Nov 2017
- Primary completion
- Jun 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of autologous adipose-derived stem/stromal cells in osteonecrosis of the femoral head (ONFH) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Safety (Serious Adverse Events) at 24 months. Started Nov 2017; status: terminated.
02
Drugs
autologous adipose-derived stem/stromal cells
03
Conditions
osteonecrosis of the femoral head (ONFH)
Beyond the preview
Go deeper on NCT03269409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03269409.